Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
A database of clinical trials and their results from Australia, New Zealand, and other countries.
account_circle
Log in
to register or update your trial
search
Search for trials
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT03829332
Registration number
NCT03829332
Ethics application status
Date submitted
1/02/2019
Date registered
4/02/2019
Date last updated
16/04/2025
Titles & IDs
Public title
Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)
Query!
Scientific title
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) in Participants With Treatment-naïve, Metastatic Nonsmall Cell Lung Cancer (NSCLC) Whose Tumors Have a Tumor Proportion Score (TPS) Greater Than or Equal to 1% (LEAP-007)
Query!
Secondary ID [1]
0
0
MK-7902-007
Query!
Secondary ID [2]
0
0
7902-007
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Non-small Cell Lung Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Lung - Mesothelioma
Query!
Cancer
0
0
0
0
Query!
Lung - Non small cell
Query!
Cancer
0
0
0
0
Query!
Lung - Small cell
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Other - Pembrolizumab
Treatment: Drugs - Lenvatinib
Treatment: Drugs - Placebo for lenvatinib
Experimental: Pembrolizumab + Lenvatinib - Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS lenvatinib 20 mg via oral capsule once daily (QD) on Days 1-21 of each 3-week cycle until progressive disease or unacceptable toxicity.
Active comparator: Pembrolizumab + Placebo - Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS placebo for lenvatinib via oral capsule QD on Days 1-21 of each 3-week cycle until progressive disease or unacceptable toxicity.
Treatment: Other: Pembrolizumab
IV infusion
Treatment: Drugs: Lenvatinib
oral capsule
Treatment: Drugs: Placebo for lenvatinib
oral capsule
Query!
Intervention code [1]
0
0
Treatment: Other
Query!
Intervention code [2]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
Query!
Assessment method [1]
0
0
PFS was defined as the time from date of randomization to the date of the first documentation of progressive disease (PD) or death from any cause, whichever occurred first. Per RECIST 1.1, PD was defined as =20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of =5 mm. The appearance of one or more new lesions was also considered PD. Data are from the product-limit (Kaplan-Meier) method for censored data. PFS as assessed by blinded independent central review (BICR) per RECIST 1.1 was presented.
Query!
Timepoint [1]
0
0
Up to approximately 25 months
Query!
Primary outcome [2]
0
0
Overall Survival (OS)
Query!
Assessment method [2]
0
0
OS was defined as the time from date of randomization to date of death from any cause. OS was presented.
Query!
Timepoint [2]
0
0
Up to approximately 25 months
Query!
Secondary outcome [1]
0
0
Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
Query!
Assessment method [1]
0
0
ORR was defined as the percentage of participants in the analysis population who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. ORR as assessed by BICR per RECIST 1.1 is presented.
Query!
Timepoint [1]
0
0
Up to approximately 25 months
Query!
Secondary outcome [2]
0
0
Number of Participants Who Experienced an Adverse Event (AE)
Query!
Assessment method [2]
0
0
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experienced an AE were reported
Query!
Timepoint [2]
0
0
Through 90 days post last dose of study treatment (Up to approximately 27 months)
Query!
Secondary outcome [3]
0
0
Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)
Query!
Assessment method [3]
0
0
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinued study treatment due to an AE were reported.
Query!
Timepoint [3]
0
0
Through last dose of study treatment (Up to approximately 24 months)
Query!
Secondary outcome [4]
0
0
Change From Baseline in European Organization for Research and Treatment (EORTC) Quality of Life Questionnaire-Core30 (QLQ-C30) Combined Global Health Status/Quality of Life (Items 29 & 30) Scale Combined Score
Query!
Assessment method [4]
0
0
EORTC QLQ-C30 is a questionnaire to assess the overall quality of life (QoL) of cancer patients. Participant responses to questions regarding Global Health Status (GHS; "How would you rate your overall health during the past week?") and QoL ("How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) is computed by averaging the raw scores of the 2 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. Per protocol, the change from baseline in GHS and QoL combined score was presented.
Query!
Timepoint [4]
0
0
Baseline and Week 21
Query!
Secondary outcome [5]
0
0
Change From Baseline in Cough (EORTC Quality of Life Questionnaire-Lung Cancer Module 13 [QLQ-LC13] Item 31) Score
Query!
Assessment method [5]
0
0
The EORTC QLQ-LC13 is a lung cancer-specific supplemental questionnaire used in combination with the EORTC QLQ-C30. Participant responses to the question "How much did you cough?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. Per protocol, the change from baseline in cough (EORTC QLQ-LC13 Item 31) score was presented.
Query!
Timepoint [5]
0
0
Baseline and Week 21
Query!
Secondary outcome [6]
0
0
Change From Baseline in Chest Pain (EORTC QLQ-LC13 Item 40) Score
Query!
Assessment method [6]
0
0
The EORTC QLQ-LC13 is a lung cancer-specific supplemental questionnaire used in combination with the EORTC QLQ-C30. Participant responses to the question "Have you had pain in your chest?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. Per protocol, the change from baseline in EORTC QLQ-LC13 chest pain (Item 40) score was presented.
Query!
Timepoint [6]
0
0
Baseline and Week 21
Query!
Secondary outcome [7]
0
0
Change From Baseline in Dyspnea (EORTC QLQ-C30 Item 8) Score
Query!
Assessment method [7]
0
0
EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to the question: "Were you short of breath?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. Per protocol, the change from baseline in EORTC QLQ-C30 dyspnea (Item 8) score was presented.
Query!
Timepoint [7]
0
0
Baseline and Week 21
Query!
Secondary outcome [8]
0
0
Change From Baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) Score
Query!
Assessment method [8]
0
0
EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 was computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. Per protocol, the change from baseline in EORTC QLQ-C30 physical functioning (Items 1-5) combined score was presented.
Query!
Timepoint [8]
0
0
Baseline and Week 21
Query!
Secondary outcome [9]
0
0
Time to True Deterioration (TTD) in EORTC QLQ-C30 Combined Global Health Status /Quality of Life (Items 29 & 30) Scale Combined Score
Query!
Assessment method [9]
0
0
EORTC QLQ-C30 is a questionnaire to assess QoL of cancer patients. Participant responses to questions on GHS ("How would you rate your overall health during the past week?") and QoL ("How would you rate your overall QoL during the past week?") were scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) was computed by averaging raw scores of the 2 items and applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD was defined as the time from baseline to first onset of =10-point negative change (decrease) from baseline in GHS-QoL combined score. A longer TTD indicates a better outcome.
Query!
Timepoint [9]
0
0
Up to approximately 25 months
Query!
Secondary outcome [10]
0
0
Time to True Deterioration (TTD) in EORTC QLQ-LC13 Cough (Item 31) Scale Score
Query!
Assessment method [10]
0
0
EORTC QLQ-LC13 is a lung cancer specific questionnaire. Participant responses to the question: "How much did you cough?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0-100. A lower score indicates a better outcome. TTD was defined as the time from baseline to first onset of =10-point negative change (decrease) from baseline in cough (Item 31). A longer TTD indicates a better outcome.
Query!
Timepoint [10]
0
0
Up to approximately 25 months
Query!
Secondary outcome [11]
0
0
Time to True Deterioration (TTD) in EORTC QLQ-LC13 Chest Pain (Item 40) Scale Score
Query!
Assessment method [11]
0
0
EORTC QLQ-LC13 is a lung cancer specific questionnaire. Participant responses to the question: "Have you had pain in your chest?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0-100. A lower score indicates a better outcome. TTD was defined as the time from baseline to first onset of =10-point negative change (decrease) from baseline in cough (Item 40). A longer TTD indicates a better outcome.
Query!
Timepoint [11]
0
0
Up to approximately 25 months
Query!
Secondary outcome [12]
0
0
Time to True Deterioration (TTD) in EORTC QLQ-C30 Dyspnea (Item 8) Scale Score
Query!
Assessment method [12]
0
0
EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to the question: "Were you short of breath?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. TTD was defined as the time from baseline to first onset of =10-point negative change (decrease) from baseline in dyspnea (Item 8). A longer TTD indicates a better outcome.
Query!
Timepoint [12]
0
0
Up to approximately 25 months
Query!
Secondary outcome [13]
0
0
Time to True Deterioration (TTD) Based on Change From Baseline in EORTC QLQ-C30 Physical Functioning (Items 1-5) Score
Query!
Assessment method [13]
0
0
EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 was computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD was defined as the time from baseline to first onset of =10-point negative change (decrease) from baseline in physical functioning (Items 1 to 5). A longer TTD indicates a better outcome.
Query!
Timepoint [13]
0
0
Up to approximately 25 months
Query!
Secondary outcome [14]
0
0
Time to True Deterioration (TTD) Based on Change From Baseline in the Composite Endpoint of Cough (EORTC QLQ-LC13 Item 31), Chest Pain (EORTC QLQ-LC13 Item 40), or Dyspnea (EORTC QLQ-C30 Item 8)
Query!
Assessment method [14]
0
0
The EORTC QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients, including a single-item scale score for dyspnea (Item 8; score range:1=Not at All to 4=Very Much). Used in combination with QLQ-C30, the EORTC QLQ-LC13 is a supplemental lung cancer-specific module, including a single-item scale score for cough (Item 31; score range:1=Not at All to 4=Very Much ) and chest pain (Item 40, score range: 1=Not at All to 4=Very Much). The combined score of items 31, 40 and 8 was computed by averaging the raw scores of the items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. The TTD in the composite endpoint of EORTC QLQ-LC13 Item 31, EORTC QLQ-LC13 Item 40, EORTC QLQ-C30 Item 8 scale score was presented, defined as the time to first onset of a =10point decrease from baseline in anyone of the three scale items. A longer TTD indicates better outcome.
Query!
Timepoint [14]
0
0
Up to approximately 25 months
Query!
Eligibility
Key inclusion criteria
* Has a histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC)
* Has Stage IV NSCLC (American Joint Committee on Cancer [AJCC 8th edition])
* Has measurable disease based on RECIST 1.1
* Has tumor tissue that demonstrates programmed cell death-ligand 1 (PD-L1) expression in =1% of tumor cells (Tumor Proportion Score [TPS] =1%) as assessed by immunohistochemistry (IHC) 22C3 pharmDx assay (Dako North America, Inc.) at a central laboratory
* Has a life expectancy of =3 months
* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days before the first dose of study treatment but before randomization
* Male participants must agree to the following during the treatment period and for =7 days after the last dose of lenvatinib/matching placebo: 1) Be abstinent from heterosexual intercourse as their preferred and usual lifestyle and agree to remain abstinent, OR 2) Must agree to use contraception unless confirmed to be azoospermic (vasectomized or secondary to medical cause)
* Female participants are eligible to participate if not pregnant or breastfeeding, and =1 of the following applies: 1) Is not a woman of child-bearing potential (WOCBP), OR 2) Is a WOCBP and is using a highly effective contraceptive method that has a low user dependency, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle during the treatment period and for =120 days post pembrolizumab or =30 days post lenvatinib/matching placebo, whichever occurs last
* Has adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP =150/90 mm Hg and no change in antihypertensive medications within 1 week before randomization
* Has adequate organ function
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Has known untreated central nervous system metastases and/or carcinomatous meningitis
* Has active hemoptysis (at least 0.5 teaspoon of bright red blood) within 2 weeks prior to the first dose of study intervention
* Has radiographic evidence of intratumoral cavitations, encasement, or invasion of a major blood vessel
* Has a known history of an additional malignancy, except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for =3 years since initiation of that therapy. (Note: The time requirement does not apply to participants who underwent successful definitive resection of basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, in situ cervical cancer, or other in situ cancers.)
* Has an active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed
* Has had an allogeneic tissue/solid organ transplant
* Has a known history of human immunodeficiency virus (HIV) infection
* Has a history of (noninfectious) pneumonitis that required systemic steroids or current pneumonitis/interstitial lung disease
* Has a known history of hepatitis B or known active hepatitis C virus infection
* Has a history of a gastrointestinal condition or procedure that in the opinion of the investigator may affect oral study drug absorption.
* Has significant cardiovascular impairment within 12 months of the first dose of study treatment, such as a history of congestive heart failure greater than New York Heart Association Class II, unstable angina, myocardial infarction, cerebrovascular accident/stroke, or cardiac arrhythmia associated with hemodynamic instability
* Has not recovered adequately from any toxicity and/or complications from major surgery before starting study treatment
* Has a known history of active tuberculosis (TB)
* Has an active infection requiring systemic therapy
* Has previously had a severe hypersensitivity reaction to treatment with a monoclonal antibody or has a known sensitivity or intolerance to any component of lenvatinib or pembrolizumab
* Has received prior systemic chemotherapy or other targeted or biological antineoplastic therapy for their metastatic NSCLC
* Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], Tumor necrosis factor receptor superfamily, member 4 [OX 40], tumor necrosis factor receptor superfamily member 9 [CD137]) or has received lenvatinib as monotherapy or in combination with anti- programmed cell death protein (anti-PD-1) agents
* Has received radiotherapy within 14 days before the first dose of study treatment or received lung radiation therapy of >30 Gray (Gy) within 6 months before the first dose of study treatment. (Note: Participants must have recovered from all radiation-related toxicities to =Grade 1, not require corticosteroids, and not have had radiation pneumonitis.)
* Has a diagnosis of immunodeficiency or is receiving any form of immunosuppressive therapy within 7 days before the first dose of study treatment
* Is receiving systemic steroid therapy (doses >10 mg daily of prednisone equivalent) within 7 days before the first dose of study treatment
* Has received a live or attenuated vaccine within 30 days before the first dose of study treatment
* Has had major surgery within 3 weeks prior to first dose of study treatment
* Has pre-existing =Grade 3 gastrointestinal or nongastrointestinal fistula
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
13/03/2019
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
24/04/2024
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
623
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Query!
Recruitment hospital [1]
0
0
Orange Health Services ( Site 0002) - Orange
Query!
Recruitment hospital [2]
0
0
Wollongong Private Hospital ( Site 0005) - Wollongong
Query!
Recruitment hospital [3]
0
0
The Prince Charles Hospital ( Site 0011) - Chermside
Query!
Recruitment hospital [4]
0
0
Ballarat Oncology and Haematology Services ( Site 0008) - Wendouree
Query!
Recruitment hospital [5]
0
0
St John of God Murdoch Medical Clinic ( Site 0001) - Perth
Query!
Recruitment postcode(s) [1]
0
0
2800 - Orange
Query!
Recruitment postcode(s) [2]
0
0
2500 - Wollongong
Query!
Recruitment postcode(s) [3]
0
0
4032 - Chermside
Query!
Recruitment postcode(s) [4]
0
0
3355 - Wendouree
Query!
Recruitment postcode(s) [5]
0
0
6150 - Perth
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alaska
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Indiana
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Kentucky
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Maryland
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Michigan
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Minnesota
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Missouri
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Montana
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
North Carolina
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Ohio
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Oregon
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Texas
Query!
Country [18]
0
0
Canada
Query!
State/province [18]
0
0
Alberta
Query!
Country [19]
0
0
Canada
Query!
State/province [19]
0
0
British Columbia
Query!
Country [20]
0
0
Canada
Query!
State/province [20]
0
0
Ontario
Query!
Country [21]
0
0
Canada
Query!
State/province [21]
0
0
Quebec
Query!
Country [22]
0
0
China
Query!
State/province [22]
0
0
Anhui
Query!
Country [23]
0
0
China
Query!
State/province [23]
0
0
Beijing
Query!
Country [24]
0
0
China
Query!
State/province [24]
0
0
Hunan
Query!
Country [25]
0
0
China
Query!
State/province [25]
0
0
Jiangsu
Query!
Country [26]
0
0
China
Query!
State/province [26]
0
0
Jilin
Query!
Country [27]
0
0
China
Query!
State/province [27]
0
0
Shanghai
Query!
Country [28]
0
0
China
Query!
State/province [28]
0
0
Shanxi
Query!
Country [29]
0
0
China
Query!
State/province [29]
0
0
Sichuan
Query!
Country [30]
0
0
China
Query!
State/province [30]
0
0
Zhejiang
Query!
Country [31]
0
0
Colombia
Query!
State/province [31]
0
0
Antioquia
Query!
Country [32]
0
0
Colombia
Query!
State/province [32]
0
0
Atlantico
Query!
Country [33]
0
0
Colombia
Query!
State/province [33]
0
0
Cesar
Query!
Country [34]
0
0
Colombia
Query!
State/province [34]
0
0
Cordoba
Query!
Country [35]
0
0
Colombia
Query!
State/province [35]
0
0
Valle Del Cauca
Query!
Country [36]
0
0
Estonia
Query!
State/province [36]
0
0
Harjumaa
Query!
Country [37]
0
0
Estonia
Query!
State/province [37]
0
0
Tartumaa
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Doubs
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
Hauts-de-Seine
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Herault
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Isere
Query!
Country [42]
0
0
France
Query!
State/province [42]
0
0
Loire-Atlantique
Query!
Country [43]
0
0
France
Query!
State/province [43]
0
0
Pyrenees-Atlantiques
Query!
Country [44]
0
0
France
Query!
State/province [44]
0
0
Seine-Maritime
Query!
Country [45]
0
0
France
Query!
State/province [45]
0
0
Somme
Query!
Country [46]
0
0
France
Query!
State/province [46]
0
0
Var
Query!
Country [47]
0
0
France
Query!
State/province [47]
0
0
Paris
Query!
Country [48]
0
0
Hungary
Query!
State/province [48]
0
0
Bekes
Query!
Country [49]
0
0
Hungary
Query!
State/province [49]
0
0
Borsod-Abauj-Zemplen
Query!
Country [50]
0
0
Hungary
Query!
State/province [50]
0
0
Gyor-Moson-Sopron
Query!
Country [51]
0
0
Hungary
Query!
State/province [51]
0
0
Jasz-Nagykun-Szolnok
Query!
Country [52]
0
0
Hungary
Query!
State/province [52]
0
0
Pest
Query!
Country [53]
0
0
Hungary
Query!
State/province [53]
0
0
Budapest
Query!
Country [54]
0
0
Hungary
Query!
State/province [54]
0
0
Kaposvar
Query!
Country [55]
0
0
Israel
Query!
State/province [55]
0
0
Heifa
Query!
Country [56]
0
0
Israel
Query!
State/province [56]
0
0
Tel Aviv
Query!
Country [57]
0
0
Israel
Query!
State/province [57]
0
0
Beer Sheva
Query!
Country [58]
0
0
Israel
Query!
State/province [58]
0
0
Haifa
Query!
Country [59]
0
0
Israel
Query!
State/province [59]
0
0
Kfar-Saba
Query!
Country [60]
0
0
Israel
Query!
State/province [60]
0
0
Petah Tikva
Query!
Country [61]
0
0
Israel
Query!
State/province [61]
0
0
?eifa
Query!
Country [62]
0
0
Italy
Query!
State/province [62]
0
0
Lazio
Query!
Country [63]
0
0
Italy
Query!
State/province [63]
0
0
Messina
Query!
Country [64]
0
0
Italy
Query!
State/province [64]
0
0
Pordenone
Query!
Country [65]
0
0
Italy
Query!
State/province [65]
0
0
Avellino
Query!
Country [66]
0
0
Italy
Query!
State/province [66]
0
0
Catanzaro
Query!
Country [67]
0
0
Italy
Query!
State/province [67]
0
0
Firenze
Query!
Country [68]
0
0
Italy
Query!
State/province [68]
0
0
Ravenna
Query!
Country [69]
0
0
Italy
Query!
State/province [69]
0
0
Roma
Query!
Country [70]
0
0
Japan
Query!
State/province [70]
0
0
Aichi
Query!
Country [71]
0
0
Japan
Query!
State/province [71]
0
0
Fukuoka
Query!
Country [72]
0
0
Japan
Query!
State/province [72]
0
0
Hyogo
Query!
Country [73]
0
0
Japan
Query!
State/province [73]
0
0
Kanagawa
Query!
Country [74]
0
0
Japan
Query!
State/province [74]
0
0
Miyagi
Query!
Country [75]
0
0
Japan
Query!
State/province [75]
0
0
Osaka
Query!
Country [76]
0
0
Japan
Query!
State/province [76]
0
0
Okayama
Query!
Country [77]
0
0
Japan
Query!
State/province [77]
0
0
Tokyo
Query!
Country [78]
0
0
Korea, Republic of
Query!
State/province [78]
0
0
Chungbuk
Query!
Country [79]
0
0
Korea, Republic of
Query!
State/province [79]
0
0
Kyonggi-do
Query!
Country [80]
0
0
Korea, Republic of
Query!
State/province [80]
0
0
Ulsan-Kwangyokshi
Query!
Country [81]
0
0
Korea, Republic of
Query!
State/province [81]
0
0
Seoul
Query!
Country [82]
0
0
Malaysia
Query!
State/province [82]
0
0
Pahang
Query!
Country [83]
0
0
Malaysia
Query!
State/province [83]
0
0
Pulau Pinang
Query!
Country [84]
0
0
Malaysia
Query!
State/province [84]
0
0
Sarawak
Query!
Country [85]
0
0
Malaysia
Query!
State/province [85]
0
0
Selangor
Query!
Country [86]
0
0
Malaysia
Query!
State/province [86]
0
0
Wilayah Persekutuan Putrajaya
Query!
Country [87]
0
0
Malaysia
Query!
State/province [87]
0
0
Kuala Lumpur
Query!
Country [88]
0
0
Mexico
Query!
State/province [88]
0
0
Distrito Federal
Query!
Country [89]
0
0
Mexico
Query!
State/province [89]
0
0
Jalisco
Query!
Country [90]
0
0
Mexico
Query!
State/province [90]
0
0
Tamaulipas
Query!
Country [91]
0
0
Mexico
Query!
State/province [91]
0
0
Mexico City
Query!
Country [92]
0
0
Mexico
Query!
State/province [92]
0
0
Oaxaca
Query!
Country [93]
0
0
Poland
Query!
State/province [93]
0
0
Lodzkie
Query!
Country [94]
0
0
Poland
Query!
State/province [94]
0
0
Lubuskie
Query!
Country [95]
0
0
Poland
Query!
State/province [95]
0
0
Malopolskie
Query!
Country [96]
0
0
Poland
Query!
State/province [96]
0
0
Mazowieckie
Query!
Country [97]
0
0
Poland
Query!
State/province [97]
0
0
Podkarpackie
Query!
Country [98]
0
0
Poland
Query!
State/province [98]
0
0
Wielkopolskie
Query!
Country [99]
0
0
Russian Federation
Query!
State/province [99]
0
0
Baskortostan, Respublika
Query!
Country [100]
0
0
Russian Federation
Query!
State/province [100]
0
0
Krasnoyarskiy Kray
Query!
Country [101]
0
0
Russian Federation
Query!
State/province [101]
0
0
Samarskaya Oblast
Query!
Country [102]
0
0
Russian Federation
Query!
State/province [102]
0
0
Sankt-Peterburg
Query!
Country [103]
0
0
Russian Federation
Query!
State/province [103]
0
0
Tatarstan, Respublika
Query!
Country [104]
0
0
Taiwan
Query!
State/province [104]
0
0
Hsinchu
Query!
Country [105]
0
0
Taiwan
Query!
State/province [105]
0
0
New Taipei
Query!
Country [106]
0
0
Taiwan
Query!
State/province [106]
0
0
Tainan
Query!
Country [107]
0
0
Taiwan
Query!
State/province [107]
0
0
Taipei
Query!
Country [108]
0
0
Turkey
Query!
State/province [108]
0
0
Adana
Query!
Country [109]
0
0
Turkey
Query!
State/province [109]
0
0
Ankara
Query!
Country [110]
0
0
Turkey
Query!
State/province [110]
0
0
Antalya
Query!
Country [111]
0
0
Turkey
Query!
State/province [111]
0
0
Izmir
Query!
Country [112]
0
0
Turkey
Query!
State/province [112]
0
0
Sakarya
Query!
Country [113]
0
0
Turkey
Query!
State/province [113]
0
0
Samsun
Query!
Country [114]
0
0
Ukraine
Query!
State/province [114]
0
0
Cherkaska Oblast
Query!
Country [115]
0
0
Ukraine
Query!
State/province [115]
0
0
Dnipropetrovska Oblast
Query!
Country [116]
0
0
Ukraine
Query!
State/province [116]
0
0
Ivano-Frankivska Oblast
Query!
Country [117]
0
0
Ukraine
Query!
State/province [117]
0
0
Kharkivska Oblast
Query!
Country [118]
0
0
Ukraine
Query!
State/province [118]
0
0
Kirovohradska Oblast
Query!
Country [119]
0
0
Ukraine
Query!
State/province [119]
0
0
Kyivska Oblast
Query!
Country [120]
0
0
Ukraine
Query!
State/province [120]
0
0
Lvivska Oblast
Query!
Country [121]
0
0
Ukraine
Query!
State/province [121]
0
0
Odeska Oblast
Query!
Country [122]
0
0
Ukraine
Query!
State/province [122]
0
0
Vinnytska Oblast
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Merck Sharp & Dohme LLC
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/industry
Query!
Name [1]
0
0
Eisai Inc.
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902/E7080) compared to pembrolizumab alone (with placebo for lenvatinib) in treatment-naïve adults with no prior systemic therapy for their metastatic non-small cell lung cancer (NSCLC) whose tumors have a programmed cell death-ligand 1 (PD-L1) Tumor Proportion Score (TPS) greater than or equal to 1%. The primary study hypotheses are that: 1) the combination of pembrolizumab and lenvatinib is superior to pembrolizumab alone as assessed by Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1); and 2) the combination of pembrolizumab and lenvatinib is superior to pembrolizumab alone as assessed by Overall Survival (OS).
Query!
Trial website
https://clinicaltrials.gov/study/NCT03829332
Query!
Trial related presentations / publications
Yang JC, Han B, De La Mora Jimenez E, Lee JS, Koralewski P, Karadurmus N, Sugawara S, Livi L, Basappa NS, Quantin X, Dudnik J, Ortiz DM, Mekhail T, Okpara CE, Dutcus C, Zimmer Z, Samkari A, Bhagwati N, Csoszi T. Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial. J Thorac Oncol. 2024 Jun;19(6):941-953. doi: 10.1016/j.jtho.2023.12.023. Epub 2023 Dec 29. Taylor MH, Schmidt EV, Dutcus C, Pinheiro EM, Funahashi Y, Lubiniecki G, Rasco D. The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors. Future Oncol. 2021 Feb;17(6):637-648. doi: 10.2217/fon-2020-0937. Epub 2020 Dec 10.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Medical Director
Query!
Address
0
0
Merck Sharp & Dohme LLC
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Query!
When will data be available (start and end dates)?
Query!
Available to whom?
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
IPD available at link: https://externaldatasharing-msd.com/
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
Study Protocol and Statistical Analysis Plan
https://cdn.clinicaltrials.gov/large-docs/32/NCT03829332/Prot_SAP_001.pdf
Statistical analysis plan
Study Protocol and Statistical Analysis Plan
https://cdn.clinicaltrials.gov/large-docs/32/NCT03829332/Prot_SAP_001.pdf
Results publications and other study-related documents
Type
Citations or Other Details
Journal
Yang JC, Han B, De La Mora Jimenez E, Lee JS, Kora...
[
More Details
]
Results are available at
https://clinicaltrials.gov/study/NCT03829332
Download to PDF